The role of Nrf2 signaling in counteracting neurodegenerative diseases.
Dinkova-Kostova AT, Kostov RV, Kazantsev AG. · 2018
Read The role of Nrf2 signaling in counteracting neurodegenerative diseases. by Dinkova-Kostova AT, Kostov RV, Kazantsev AG. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6221096.txt.
Introduction
Dinkova-Kostova and co-authors review a defence factor called Nrf2 in brain disease. Nrf2 sits where cell redox and metabolism meet. Its target genes make antioxidant enzymes. They also help clear damaged proteins and organelles. The review appeared in The FEBS Journal.
Nrf2 function changes in many brain disorders. They include Huntington's, Alzheimer's, and motor neurone disease. Friedreich's ataxia is also covered. Turning Nrf2 on eases several disease processes. It boosts antioxidant defences and calms inflammation. It improves mitochondrial function and protein balance. Small drug activators protected animal models of these diseases. They also protected human cells with mutant proteins. The authors see Nrf2 as a strong drug target.
Catalog record
| CREATOR | Dinkova-Kostova AT, Kostov RV, Kazantsev AG. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 70 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The role of Nrf2 signaling in counteracting neurodegenerative diseases By Albena T. Dinkova‐Kostova, Rumen V. Kostov, Aleksey G. Kazantsev Published in: The Febs Journal DOI: 10.1111/febs.14379 ABSTRACT The transcription factor Nrf2 (nuclear factor‐erythroid 2 p45‐related factor 2) functions at the interface of cellular redox and intermediary metabolism. Nrf2 target genes encode antioxidant enzymes, and proteins involved in xenobiotic detoxification, repair and removal of damaged proteins and organelles, inflammation, and mitochondrial bioenergetics. The function of Nrf2 is altered in many neurodegenerative disorders, such as Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, and Friedreich's ataxia. Nrf2 activation mitigates multiple pathogenic processes involved in these neurodegenerative disorders through upregulation of antioxidant defenses, inhibition of inflammation, improvement of mitochondrial function, and maintenance of protein homeostasis. Small molecule pharmacological activators of Nrf2 have shown protective effects in numerous animal models of neurodegenerative diseases, and in cultures of human cells expressing mutant proteins. Targeting Nrf2 signaling may provide a therapeutic option to delay onset, slow progression, and ameliorate symptoms of neurodegenerative disorders. AbbreviationsADAlzheimer's diseaseALSamyotrophic lateral sclerosisAMPKAMP‐activated protein kinaseAPPamyloid precursor proteinARE/EpREantioxidant/electrophile response elementAβamyloid‐βCATcatalaseERKextracellular signal‐regulated kinasesFRDAFriedreich's ataxiaFTLDfrontotemporal lobar degenerationGPXglutathione peroxidaseGSHreduced glutathioneGSK3glycogen synthase kinase 3GSTglutathione S‐transferaseHDHuntington's diseaseHFDhigh‐fat dietHO‐1heme oxygenase 1HTThuntingtinILinterleukinKeap1Kelch‐like ECH‐associated protein 1MPP+positively charged 1‐methyl‐4‐phenylpyridiniumMPTP1‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridineNQO1NAD(P)H: quinone oxidoreductase 1Nrf2nuclear factor‐erythroid 2 p45‐related factor 2PDParkinson's diseasePGC‐1αproliferator‐activated receptor gamma coactivator 1αROSreactive oxygen speciesSCFSkp, Cullin, F‐box containing complexSOD1superoxide dismutase 1tBHQ tert‐butyl‐hydroquinoneTNF‐αtumor necrosis factor alpha INTRODUCTION The transcription factor Nrf2 (nuclear factor erythroid 2 p45‐related factor 2) regulates the expression of genes involved in cellular protection against damage by oxidants, electrophiles, and inflammatory agents, and in the maintenance of mitochondrial function, cellular redox, and protein homeostasis 1. Nrf2 protein comprises seven functional domains termed Nrf2‐ECH homology (Neh) 1–7 domains (Fig. 1). Nrf2 binds one of its major negative regulators, Kelch‐like ECH‐associated protein 1 (Keap1) through its N‐terminal Neh2 domain. Neh4 and Neh5 are transactivation domains that recruit cAMP response element‐binding protein (CREB)‐binding protein (CBP) and/or receptor‐associated coactivator 3 (RAC3). The Neh7 domain mediates binding to retinoid X receptor alpha (RXRα), another negative regulator of Nrf2. The Neh6 domain mediates interaction with a third negative regulator, β‐transducin repeat‐containing protein (β‐TrCP). Neh1 is responsible for the formation of a heterodimer with small musculoaponeurotic fibrosarcoma (sMaf) proteins, and mediates binding to antioxidant/electrophile response element (ARE/EpRE) sequences in the promoter regions of Nrf2 target genes. Finally, the C terminus Neh3 is another transactivation domain that recruits chromo‐ATPase/helicase DNA‐binding protein 6 (CHD6). [Figure: Domain structure of Nrf2. The low affinity binding ‘DLG’ motif and the high affinity binding ‘ETGE’ motif in the N‐terminal Neh2 domain, through which Nrf2 binds to Keap1, are indicated. Also shown is the phosphodegron in the Neh6 domain through which, following phosphorylation by glycogen synthase kinase 3 (GSK3), Nrf2 binds to β‐transducin repeat‐containing protein (β‐TrCP).] Nrf2 levels are regulated primarily by ubiquitination and proteasomal degradation (Fig. 2). After binding to the Neh2 domain, Keap1 mediates the Cullin3 (Cul3)/Rbx1‐dependent ubiquitination of Nrf2 2, 3, 4. Additionally, the Neh6 domain contains a phosphodegron for β‐TrCP/Cullin1‐mediated ubiquitination 5, 6. Synoviolin (Hrd1) and WDR23‐DDB1‐Cul4 are two other ubiquitin ligases that have been shown to participate in the proteasomal degradation of Nrf2 7, 8. [Figure: Regulation of Nrf2 by ubiquitination and proteasomal degradation. Four known ubiquitin ligase systems mediate the degradation of Nrf2: Keap1, a substrate adaptor protein for Cul3/Rbx1‐based ubiquitin ligase and a cysteine‐based sensor for Nrf2 inducers; β‐TrCP, a substrate adaptor for Skp1‐Cul1/Rbx1‐based ubiquitin ligase, WDR23‐DDB1‐Cul4//Roc1‐based ubiquitin ligase, and Hrd1. Keap1‐mediated degradation requires that its cysteine sensors are in reduced state. β‐TrCP‐mediated degradation requires formation of a phosphodegron catalyzed by glycogen synthase kinase 3 (GSK3), which in turn requires phosphorylation by a priming kinase. Hrd1‐mediated degradation of Nrf2 occurs during ER stress.] At homeostatic conditions, Nrf2 is a short‐lived protein. Under stress conditions, Nrf2 is stabilized and translocates to the nucleus, where it binds (as a heterodimer with a member of the small Maf family of transcription factors) to the ARE/EpRE sequences in the promoter of its target genes, and activates their transcription. Nrf2 targets include genes that encode detoxification, antioxidant, and anti‐inflammatory proteins as well as proteins involved in the regulation of autophagy and clearance of damaged proteins, such as proteasomal subunits 9, 10, 11. Activation of Nrf2 leads to the upregulation of proteins involved in the synthesis of glutathione, the main intracellular small molecule antioxidant 12, 13, and NADPH, which provides reducing equivalents for the regeneration of reduced glutathione (GSH) from its oxidized form, GSSG 14, 15, 16, 17. Nrf2 also participates in the maintenance of mitochondrial function 18, 19 and quality control, through activation of mitophagy 20, 21. Nrf2 inhibits the transcription of genes encoding proinflammatory cytokines and suppresses proinflammatory responses following exposure to ultraviolet radiation 22 or lipopolysaccharide (LPS) 23. Such comprehensive cytoprotective functions suggest potential benefits of therapeutic targeting of Nrf2 to counteract neurodegeneration. NRF2 IN NEURODEGENERATIVE DISEASES Aging is the primary risk factor for developing neurodegenerative diseases 24. The prevalence of age‐dependent neurodegenerative disorders, such as Alzheimer's disease (AD) and Parkinson's disease (PD), is projected to increase due to population aging 25, with a corresponding increase in the associated socioeconomic impact. Genetic and environmental risk factors also contribute to the development of neurodegenerative diseases. Currently, there is no disease‐modifying therapy for any neurodegenerative disease; and even in conditions where symptomatic treatments are available, the therapeutic benefit is limited. Although the clinical manifestations and genetic causes of neurodegenerative diseases are distinct, several of these disorders share strikingly similar pathological mechanisms, including mitochondrial impairment, excessive levels of reactive oxygen species (ROS), neuroinflammation, and disturbances in protein homeostasis (proteostasis) 24. Additionally, there is an age‐associated increase in oxidative damage to the brain, leading to mitochondrial dysfunction, dopamine auto‐oxidation, α‐synuclein aggregation, glial cell activation, alterations in calcium signaling, and excess free iron 26. Dopaminergic neurons show linear decline of 5–10% per decade with aging, and this process is accelerated in PD patients. A meta‐analysis of PD and AD microarray datasets identified 31 common downregulated genes containing the ARE/EpRE consensus sequence in their promoters, in addition to increased levels of Nrf2 27. Increased oxidative stress was observed in human peripheral blood mononuclear cells isolated from individuals with mild cognitive impairment and from 3‐month‐old 3xTg‐AD male mice, which was due to increased levels of nuclear Nrf2 and reduced superoxide dismutase 1 (SOD1) mRNA in the brain cortex 28. The AT‐Nrf2‐knockout mouse model, that combines amyloidopathy and tauopathy with Nrf2 deficiency, presents increased markers of oxidative stress and neuroinflammation in the brain tissue compared to AT‐Nrf2‐wild‐type mice 29. Furthermore, young adult AT‐Nrf2‐knockout mice have deficits in spatial learning and memory and reduced long‐term potentiation in the perforant pathway. Transcriptomic analysis has shown that Nrf2‐knockout mouse brains share 7 and 10 of the most dysregulated pathways with aging human and AD brains, respectively 29. OXIDATIVE STRESS IN NEURODEGENERATIVE DISEASE AND THE COUNTERACTING ROLE OF NRF2 The brain is especially sensitive to changes in cellular redox status; therefore, maintaining redox homeostasis in the brain is critical for preventing oxidative stress‐induced cellular damage 24, 25. Nrf2 regulates the expression of a variety of antioxidant enzymes and proteins that exert cytoprotective effects, and there is mounting evidence demonstrating improvement of neurological phenotypes in disease models following the induction of Nrf2‐dependent antioxidant activities. Synaptic degeneration and neuronal death that characterize AD